Combined Haploidentical-Cord Blood Transplantation for Adults and Children

NACompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

October 9, 2006

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
LeukemiaMyelodysplastic SyndromeMultiple MyelomaLymphoma
Interventions
DRUG

Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)

Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.

PROCEDURE

Stem Cell Transplant

Infusion of haploidentical donor, umbilical cord blood

PROCEDURE

Stem Cells Collections

Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.

DRUG

Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)

Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.

DRUG

Fludarabine, Busulfan, and ATG

Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.

Trial Locations (1)

60637

The University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT00943800 - Combined Haploidentical-Cord Blood Transplantation for Adults and Children | Biotech Hunter | Biotech Hunter